CSPHF Stock - CStone Pharmaceuticals
Unlock GoAI Insights for CSPHF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $407.20M | $463.84M | $481.36M | $243.72M | $1.04B |
| Gross Profit | $240.15M | $304.30M | $278.38M | $136.89M | $797.41M |
| Gross Margin | 59.0% | 65.6% | 57.8% | 56.2% | 76.8% |
| Operating Income | $-91,692,000 | $-579,845,000 | $-912,147,000 | $-1,829,443,000 | $-1,091,931,000 |
| Net Income | $-91,207,000 | $-367,234,000 | $-902,678,000 | $-1,920,100,000 | $-1,219,902,000 |
| Net Margin | -22.4% | -79.2% | -187.5% | -787.8% | -117.4% |
| EPS | $-0.07 | $-0.29 | $-0.77 | $-1.65 | $-1.17 |
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor to treat hepatocellular carcinoma. Its products also comprise CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Shanghai, China.
Visit WebsiteEarnings History & Surprises
CSPHFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 25, 2026 | — | — | — | — |
Q3 2025 | Aug 14, 2025 | $-0.01 | $-0.01 | -2.7% | ✗ MISS |
Q1 2025 | Mar 25, 2025 | $-0.00 | $-0.01 | -166.7% | ✗ MISS |
Q4 2024 | Dec 31, 2024 | — | $-0.01 | — | — |
Q3 2024 | Aug 23, 2024 | $-0.01 | $0.00 | +112.3% | ✓ BEAT |
Q1 2024 | Mar 27, 2024 | $-0.01 | $-0.02 | -30.0% | ✗ MISS |
Q1 2024 | Jan 17, 2024 | — | $-0.02 | — | — |
Q2 2023 | Jun 30, 2023 | $-0.04 | $-0.02 | +42.3% | ✓ BEAT |
Q1 2023 | Mar 15, 2023 | $-0.06 | $-0.07 | -12.2% | ✗ MISS |
Q4 2022 | Dec 31, 2022 | — | $-0.07 | — | — |
Q3 2022 | Aug 25, 2022 | $-0.06 | $-0.05 | +25.0% | ✓ BEAT |
Q2 2022 | May 31, 2022 | $-0.11 | $-0.15 | -42.0% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | — | $-0.15 | — | — |
Q3 2021 | Aug 26, 2021 | $-0.13 | $-0.10 | +18.4% | ✓ BEAT |
Q1 2021 | Mar 25, 2021 | $-0.14 | $-0.08 | +45.2% | ✓ BEAT |
Q4 2020 | Dec 31, 2020 | — | $-0.08 | — | — |
Q3 2020 | Aug 18, 2020 | $-0.11 | $-0.09 | +13.7% | ✓ BEAT |
Q1 2020 | Mar 26, 2020 | $-0.09 | $-0.16 | -74.2% | ✗ MISS |
Q4 2019 | Dec 31, 2019 | — | $-0.16 | — | — |
Q3 2019 | Aug 15, 2019 | — | $-0.24 | — | — |
Latest News
Frequently Asked Questions about CSPHF
What is CSPHF's current stock price?
What is the analyst price target for CSPHF?
What sector is CStone Pharmaceuticals in?
What is CSPHF's market cap?
Does CSPHF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to CSPHF for comparison